Published in Br Med J on March 08, 1980
Monkey B virus (Cercopithecine herpesvirus 1). Comp Med (2008) 1.27
Postexposure immunoprophylaxis against B virus (Herpesvirus simiae) infection. Br Med J (Clin Res Ed) (1981) 1.07
Screening donors for xenotransplantation. The potential for xenozoonoses. Transplantation (1994) 0.97
Postexposure immunoprophylaxis against B virus infection. Br Med J (Clin Res Ed) (1982) 0.91
Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides. Antimicrob Agents Chemother (2007) 0.80
Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds. Antimicrob Agents Chemother (2009) 0.77
Papiine herpesvirus 2 as a predictive model for drug sensitivity of Macacine herpesvirus 1 (monkey B virus). Comp Med (2014) 0.75
Acyclovir therapy of neonatal herpes simplex virus type 2 infections in rabbits. Antimicrob Agents Chemother (1981) 0.75
Risk of occupational exposure to Herpesvirus simiae (B virus) in Quebec. CMAJ (1990) 0.75
Prophylaxis against B virus infection. BMJ (1988) 0.75
Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci U S A (1977) 11.20
9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature (1978) 9.21
Growth inhibition by acycloguanosine of herpesviruses isolated from human infections. Antimicrob Agents Chemother (1979) 3.61
Efficacy of acycloguanosine (Wellcome 248U) against herpes-simplex corneal ulcers. Lancet (1979) 2.90
Latent herpes simplex virus infections in sensory ganglia of hairless mice prevented by acycloguanosine. Antimicrob Agents Chemother (1979) 2.10
Acycloguanosine for viral pneumonia. Lancet (1979) 1.07
Modification of the colorimetric assay for chloramphenicol in the presence of bilirubin. Antimicrob Agents Chemother (1979) 0.95
9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature (1978) 9.21
An antigenic difference between intracellular and extracellular rabbitpox virus. J Gen Virol (1971) 4.61
Differences between extracellular and intracellular forms of poxvirus and their implications. Prog Med Virol (1973) 3.19
Vagal reflexes appearing in asphyxia in rabbits at different ages. J Physiol (1939) 2.58
Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet (1999) 2.40
The effect of asphyxia upon the heart rate of rabbits at different ages. J Physiol (1938) 2.02
Experimental respiratory infection with poxviruses. I. Clinical virological and epidemiological studies. Br J Exp Pathol (1966) 2.00
Relative potencies of anti-herpes compounds. Ann N Y Acad Sci (1977) 1.98
Evaluation of different indirect measures of rate of drug absorption in comparative pharmacokinetic studies. J Pharm Sci (1994) 1.95
The activity in vitro against herpes virus of 9-(2-hydroxyethoxymethyl)guanine (acycloguanosine), a new antiviral agent. J Antimicrob Chemother (1979) 1.85
4',6-Dichloroflavan (BW683C), a new anti-rhinovirus compound. Nature (1981) 1.69
The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort. Neurology (2005) 1.62
The nature of the immune state produced by inactivated vaccinia virus in rabbits. Am J Epidemiol (1971) 1.54
Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet (1999) 1.54
Clinical experience with the antiviral drug marboran (1-methylisatin 3-thiosemicarbazone). Ann N Y Acad Sci (1965) 1.49
Prophylaxis of smallpox with methisazone. Am J Epidemiol (1969) 1.46
Comparison of activity of herpes virus inhibitors. J Antimicrob Chemother (1977) 1.40
Antiviral chemotherapy. Mod Trends Med Virol (1967) 1.39
Protection against poxviruses. Proc R Soc Med (1969) 1.38
Treatment of experimental herpes simplex keratitis with acycloguanosine. Br J Ophthalmol (1979) 1.36
Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro. Antimicrob Agents Chemother (1998) 1.31
Common noncompartmental pharmacokinetic variables: are they normally or log-normally distributed? J Biopharm Stat (1997) 1.27
Specific and sensitive method for the determination of aspirin and salicylic acid in plasma using reversed-phase high-performance liquid chromatography. J Chromatogr (1980) 1.26
Biological activities of some purine arabinosides. Ann N Y Acad Sci (1975) 1.25
Australia antigen in urine. Lancet (1971) 1.18
Adenovirus multiplication: inhibition by methisazone. Science (1966) 1.18
Pharmacodynamics of abacavir in an in vitro hollow-fiber model system. Antimicrob Agents Chemother (2002) 1.16
Excretion of B virus in monkeys and evidence of genital infection. Lab Anim (1984) 1.16
Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. Br J Clin Pharmacol (1996) 1.13
Fluticasone propionate--an update on preclinical and clinical experience. Respir Med (1995) 1.11
Delayed onset of encephalitis in mice passively immunised against Semliki Forest virus. Br J Exp Pathol (1971) 1.10
Efficient atmospheric cleansing of oxidized organic trace gases by vegetation. Science (2010) 1.09
Elevated peripheral neutrophils and matrix metalloproteinase 9 as biomarkers of functional outcome following subarachnoid hemorrhage. Transl Stroke Res (2011) 1.08
Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir. Antimicrob Agents Chemother (2000) 1.07
Postexposure immunoprophylaxis against B virus (Herpesvirus simiae) infection. Br Med J (Clin Res Ed) (1981) 1.07
Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin Pharmacokinet (1999) 1.04
The isolation of monkey B virus (Herpesvirus simiae) from the trigeminal ganglia of a healthy seropositive rhesus monkey. J Biol Stand (1975) 1.04
Bioavailability of orally administered micronised fluticasone propionate. Clin Pharmacokinet (2000) 1.04
Cost-effectiveness of coronary artery bypass surgery in octogenarians. Ann Surg (1998) 1.02
The relative potencies of anti-influenza compounds. Ann N Y Acad Sci (1977) 1.01
Effect of renal impairment on the pharmacokinetics of intravenous zanamivir. Clin Pharmacokinet (1999) 0.99
Absorption kinetics after inhalation of fluticasone propionate via the Diskhaler, Diskus and metered-dose inhaler in healthy volunteers. Clin Pharmacokinet (2000) 0.99
Rational dose selection for a nonnucleoside reverse transcriptase inhibitor through use of population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother (2002) 0.99
Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. J Clin Pharmacol (1996) 0.98
Experimental respiratory infection with poxviruses. II. Pathological studies. Br J Exp Pathol (1966) 0.95
Human pharmacokinetics of acyclovir (an antiviral agent) following rapid intravenous injection. J Antimicrob Chemother (1981) 0.94
A pilot study: use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures. J Rheumatol (1999) 0.93
Antiviral chemotherapy: the first decade. Br Med J (1973) 0.92
The older cardiac transplant donor. Relation to graft function and recipient survival longer than 6 years. Circulation (1989) 0.91
Latent infection of monkeys with B virus and prophylactic studies in a rabbit model of this disease. J Antimicrob Chemother (1977) 0.91
The relationship between systemic exposure to fluticasone propionate and cortisol reduction in healthy male volunteers. Clin Pharmacokinet (2000) 0.89
Multiple methicillin-resistant Staphylococcus aureus strains as a cause for a single outbreak of severe disease in hospitalized neonates. Pediatr Infect Dis J (1992) 0.88
Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir. Respir Med (2000) 0.88
Health behaviors and depressive symptoms in testicular cancer survivors. Urology (2007) 0.87
A study of concentrations of trimethoprim-sulphamethoxazole in the human prostate gland. Br J Urol (1976) 0.87
Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy volunteers. Clin Pharmacokinet (2000) 0.86
A comparison of neutralization tests for the detection of antibodies to Herpesvirus simiae (monkey B virus). Lab Anim Sci (1982) 0.86
The site of inversion of R(-)-ibuprofen: studies using rat in-situ isolated perfused intestine/liver preparations. J Pharm Pharmacol (1991) 0.85
Mixed effect modeling of sumatriptan pharmacokinetics during drug development. I: Interspecies allometric scaling. J Pharmacokinet Biopharm (1997) 0.85
Impact of defoliation intensity and frequency on N uptake and mobilization in Lolium perenne. J Exp Bot (2006) 0.85
Simple high-performance liquid chromatographic method for the analysis of 9-(2-hydroxyethoxymethyl)guanine (acyclovir) in human plasma and urine. J Chromatogr (1981) 0.84
Deposition and disposition of [11C]zanamivir following administration as an intranasal spray. Evaluation with positron emission tomography. Clin Pharmacokinet (1999) 0.84
Evaluation of an automatic seizure detection method for the newborn EEG. Electroencephalogr Clin Neurophysiol (1997) 0.83
Human gastrointestinal absorption of acyclovir from tablet duodenal infusion and sipped solution. Br J Clin Pharmacol (1986) 0.83
Population pharmacokinetic-pharmacodynamic model of craving in an enforced smoking cessation population: indirect response and probabilistic modeling. Pharm Res (2001) 0.83
A comparison of test methods in influenza chemotherapy. J Antimicrob Chemother (1975) 0.83
Effects of environmental chemicals on the metabolism of drugs, carcinogens, and normal body constituents in man. Ann N Y Acad Sci (1971) 0.82
Human safety and pharmacokinetics of a single intramuscular dose of a novel spectinomycin analog, trospectomycin (U-63,366F). Antimicrob Agents Chemother (1990) 0.82
The disposition of bupropion and its metabolites in healthy male volunteers after single and multiple doses. Eur J Clin Pharmacol (1985) 0.81
Sex-related differences in the bone mineral density of atrophic mandibles. J Prosthet Dent (1994) 0.81
A history of the discovery and clinical application of antiviral drugs. Br Med Bull (1985) 0.80
Transmission of B virus infection between monkeys especially in relation to breeding colonies. Lab Anim (1984) 0.80
The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine. Br J Clin Pharmacol (1994) 0.80
Pharmacokinetics of trospectomycin sulphate in healthy subjects after single intravenous and intramuscular doses. Br J Clin Pharmacol (1991) 0.80
The development and use of microcarrier and glass sphere culture techniques for the production of herpes simplex viruses. Dev Biol Stand (1981) 0.80
The determination of allopurinol and oxipurinol in human plasma and urine. J Chromatogr (1977) 0.80
Report of twelve years experience in open study of Skinner herpes simplex vaccine towards prevention of herpes genitalis. Med Microbiol Immunol (1992) 0.79
Reappraisal of histologic features of the acute cutaneous graft-versus-host reaction based on an allogeneic rodent model. J Invest Dermatol (1994) 0.79
The biosynthesis of 4-hydroxycoumarin and dicoumarol by Aspergillus fumigatus Fresenius. Biochem J (1970) 0.79
Evaluation of different partial AUCs as indirect measures of rate of drug absorption in comparative pharmacokinetic studies. Eur J Pharm Sci (1998) 0.79
Alcohol and bupropion pharmacokinetics in healthy male volunteers. Eur J Clin Pharmacol (1984) 0.79
Use of interferon in the management of patients with subacute sclerosing panencephalitis. Dev Med Child Neurol (1985) 0.78
Herpes simplex virus genital infection of the female guinea pig as a model for the evaluation of an experimental vaccine. Vaccine (1984) 0.78
Patient education program to teach energy conservation behaviors to patients with rheumatoid arthritis: a pilot study. Arch Phys Med Rehabil (1987) 0.78
Sensitive assay for pseudoephedrine and its metabolite, norpseudoephedrine in plasma and urine using gas--liquid chromatography with electron-capture detection. J Chromatogr (1981) 0.78
Personality correlates of the Hypercompetitive Attitude Scale: validity tests of Horney's theory of neurosis. J Pers Assess (1994) 0.78
Transport characteristics of the anti-human immunodeficiency virus nucleoside analog, abacavir, into brain and cerebrospinal fluid. J Pharmacol Exp Ther (2001) 0.77
Effect of a single oral dose of aspirin on the platelet aggregation response to arachidonic acid. Br J Clin Pharmacol (1979) 0.77
Effects of piperonyl butoxide on drug metabolism in rodents and man. Arch Environ Health (1972) 0.77
Systemic exposure to fluticasone propionate administered via metered-dose inhaler containing chlorofluorocarbon or hydrofluoroalkane propellant. Clin Pharmacokinet (2000) 0.76
Letter: Vaccination of smallpox contacts. Br Med J (1974) 0.76
The antigenicity and immunogenicity of the intracellular and extracellular forms of vaccinia virus. I: The production of high-titre vaccinia extracellular virus and its antigenicity after inactivation. Br J Exp Pathol (1980) 0.76
Computer-assisted drug development (CADD): an emerging technology for designing first-time-in-man and proof-of-concept studies from preclinical experiments. Eur J Pharm Sci (2001) 0.76
Postexposure immunoprophylaxis against B virus infection. Br Med J (Clin Res Ed) (1982) 0.76
Constant infusion and bolus injection of stable-label tracer give reproducible and comparable fasting HGO. Am J Physiol (1997) 0.76
Concentrations of trimethoprim and sulphamethoxazole in aqueous humour and plasma from regimens of co-trimoxazole in man. J Antimicrob Chemother (1975) 0.75
The dosage of co-trimoxazole in childhood. Eur J Clin Pharmacol (1975) 0.75
Herpes simplex vaccine using cell membrane associated antigen in an animal model. Dev Biol Stand (1981) 0.75